MedinCell Company Description

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.

It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults.

The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.

Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria.

MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.